{"denoms":[{"counts":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"64"}],"units":"Participants"}],"groups":[{"description":"Participants received MIRCERA IV injection at a starting dose based on an intermediate conversion factor from their previous ESA dose (4 \\* previous weekly epoetin dose \\[IU\\]/250 or 4 \\* previous weekly darbepoetin alfa dose \\[mcg\\]/1.1) once every 4 weeks for 20 weeks. Participants who completed the 20 weeks of treatment and had Hb level within ± 1 g/dL of their baseline Hb level and within the target range of 10-12 g/dL, entered an optional 52-weeks safety extension period. During this period, the participants continued to receive MIRCERA IV injection once every 4 weeks.","id":"BG000","title":"MIRCERA Group 1: Intermediate-Conversion-Factor Group"},{"description":"Participants received MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 \\* previous weekly epoetin dose \\[IU\\]/125 or 4 \\* previous weekly darbepoetin alfa dose \\[mcg\\]/0.55) once every 4 weeks for 20 weeks. Participants who completed the 20 weeks of treatment and had Hb level within ± 1 g/dL of their baseline Hb level and within the target range of 10-12 g/dL, entered an optional 52-weeks safety extension period. During this period, the participants continued to receive MIRCERA IV injection once every 4 weeks.","id":"BG001","title":"MIRCERA Group 2: High-Conversion-Factor Group"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.24","value":"11.3"},{"groupId":"BG001","spread":"3.06","value":"13.0"},{"groupId":"BG002","spread":"3.17","value":"12.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"30"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"34"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Intention-to-treat (ITT) population included all enrolled participants."}